Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Simulations Plus Inc is a health information services business based in the US. Simulations Plus shares (SLP) are listed on the NASDAQ and all prices are listed in US Dollars. Simulations Plus employs 135 staff and has a trailing 12-month revenue of around $52 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Latest market close | $48.54 |
|---|---|
| 52-week range | $35.10 - $67.59 |
| 50-day moving average | $60.27 |
| 200-day moving average | $49.49 |
| Wall St. target price | $65.25 |
| PE ratio | 84.9474 |
| Dividend yield | $0.24 (0.5%) |
| Earnings per share (TTM) | $0.57 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $48.54 from 2022-09-27
| 1 week (2022-09-22) | -1.44% |
|---|---|
| 1 month (2022-08-25) | N/A |
| 3 months (2022-06-29) | -0.19% |
| 6 months (2022-03-29) | 0.08% |
| 1 year (2021-09-29) | 23.07% |
|---|---|
| 2 years (2020-09-29) | -35.11% |
| 3 years (2019-09-27) | 42.68% |
| 5 years (2017-09-29) | 213.16% |
Valuing Simulations Plus stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Simulations Plus's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Simulations Plus's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 85x. In other words, Simulations Plus shares trade at around 85x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Simulations Plus's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 9.7712. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Simulations Plus's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Simulations Plus's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $16.7 million.
The EBITDA is a measure of a Simulations Plus's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $52 million |
|---|---|
| Operating margin TTM | 27.67% |
| Gross profit TTM | $35.9 million |
| Return on assets TTM | 4.92% |
| Return on equity TTM | 6.9% |
| Profit margin | 22.74% |
| Book value | $8.78 |
| Market capitalisation | $979.8 million |
TTM: trailing 12 months
Dividend payout ratio: 42.11% of net profits
Recently Simulations Plus has paid out, on average, around 42.11% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.5% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Simulations Plus shareholders could enjoy a 0.5% return on their shares, in the form of dividend payments. In Simulations Plus's case, that would currently equate to about $0.24 per share.
While Simulations Plus's payout ratio might seem fairly standard, it's worth remembering that Simulations Plus may be investing much of the rest of its net profits in future growth.
Simulations Plus's most recent dividend payout was on 31 July 2022. The latest dividend was paid out to all shareholders who bought their shares by 21 July 2022 (the "ex-dividend date").
Simulations Plus's shares were split on a 2:1 basis on 1 October 2007. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Simulations Plus shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Simulations Plus shares which in turn could have impacted Simulations Plus's share price.
Over the last 12 months, Simulations Plus's shares have ranged in value from as little as $35.1015 up to $67.59. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Simulations Plus's is 0.4415. This would suggest that Simulations Plus's shares are less volatile than average (for this exchange).
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
We’ve rounded up stats on some of the most popular wheat stocks, along with information on how these stocks compare and how to invest.